Mammalian fertility absolutely depends on synchronized development of the blastocyst to the stage when it is competent to implant, and the uterus to the stage when it is receptive to implantation. However, the molecular basis for the reciprocal interaction between the embryo and the uterus remains largely unexplored. One potentially important mechanism involves signaling between an evolutionarily conserved G protein-coupled protein cannabinoid receptor, CB1, that is expressed at high levels on the surface of the trophectoderm and anandamide (N-arachidonoylethanolamine), an endocannabinoid ligand found to be produced at higher levels by the uterus before implantation and then down-regulated at the time of implantation. Using genetic, pharmacological, and physiological approaches, we show here that anandamide within a very narrow range regulates blastocyst function and implantation by differentially modulating mitogenactivated protein kinase signaling and Ca 2؉ channel activity via CB1 receptors. Anandamide at a low concentration (7 nM) induces extracellular regulated kinase phosphorylation and nuclear translocation in trophectoderm cells without influencing Ca 2؉ channels, and renders the blastocyst competent for implantation in the receptive uterus. In contrast, anandamide at a higher concentration (28 nM) inhibits Ca 2؉ channel activity and blastocyst competency for implantation without influencing mitogen-activated protein kinase signaling. Besides uncovering a potentially important regulatory mechanism for synchronizing blastocyst and uterine competency to implantation, this observation has high clinical relevance, because elevated levels of anandamide induce spontaneous pregnancy loss in women.
N
atural and endogenous cannabinoids function as ligands for G protein (G i/o , GTP-binding proteins sensitive to pertussis toxin)-coupled cannabinoid receptors, CB1 (brain type) and CB2 (spleen type) (1) (2) (3) . Activation of CB receptors inhibits adenylyl cyclase activity and voltage-gated Ca 2ϩ channels but stimulates mitogen-activated protein kinase (MAPK) signaling (4, 5) . Cannabinoids exert a broad array of central and peripheral effects including adverse effects on fertilization, embryonic development, and pregnancy (6, 7) . Our previous observations of functional expression of CB1 in the preimplantation mouse embryo (8, 9) , anandamide synthesis in the uterus (10, 11) , and the dose-and stage-specific effects of anandamide on embryo development and implantation suggest that ligand-receptor signaling with endocannabinoids is important for embryo development and implantation (12, 13) . The levels of anandamide in the uterus and CB1 in the blastocyst were found to be higher than in the brain during early pregnancy in mice (9, 10) . Furthermore, uterine levels of anandamide and blastocyst CB1 were coordinately down-regulated with the attainment of uterine receptivity and blastocyst activation before implantation in contrast to higher levels retained in delayed implanting uterus and dormant blastocysts (10, 11) . These results suggested that although the lower levels of anandamide and cannabinoid receptors are beneficial for implantation, the higher levels are detrimental to this process. Indeed, we previously observed that a lower concentration of anandamide stimulates blastocyst outgrowth in culture, but at a higher concentration it inhibits this event (12) . Similar biphasic effects of anandamide have also been noted for other physiological functions in mice (6, 14, 15) . However, the mechanism of differential effects of endocannabinoids is still unknown. The reduced Mendelian frequency of homozygous mutant offspring born from heterozygous crossing of CB1 mutant mice (16) and subfertility among CB1 mutant females with 40% pregnancy losses (11) further indicate that regulated endocannabinoid signaling is critical to the establishment of normal pregnancy, although the mechanism by which this signaling influences pregnancy remains mostly unknown. Here, we have combined genetic, pharmacological, cell biological, and physiological approaches to address this question with respect to blastocyst activation and implantation in mice. We show that anandamide at a low concentration activates extracellular regulated kinase (ERK) signaling in dormant blastocysts via their trophectoderm cell surface CB1 and renders them competent for implantation in the receptive uterus. Conversely, anandamide at a higher concentration inhibits Ca 2ϩ mobilization and fails to induce blastocyst competency without influencing ERK signaling.
Materials and Methods
Animal Models, Blastocyst Culture͞Transfer, and Treatments. Adult WT, CB1, and CB2 mutant mice were housed in the Institutional Animal Care Facility according to National Institutes of Health and institutional guidelines for laboratory animals. The conditions of delayed implantation were induced by ovariectomizing pregnant or pseudopregnant (day 1 ϭ vaginal plug) mice on the morning of day 4 (0830-0900 hours) and maintained by daily injections of progesterone (P 4 , 2 mg per mouse) from day 5 until the mice were killed. Activation of dormant blastocysts in P 4 -primed delayed implanting pregnant mice was induced by giving a single injection of estradiol-17␤ (E 2 , 25 ng per mouse). To study the effects of anandamide on MAPK signaling, blastocysts were cultured in Whitten's medium in the absence or presence of anandamide (Cayman Chemical, Ann Arbor, MI) as initially described (17) . To examine the specificity of anandamide induced activation of MAPK via CB receptors, blastocysts were preincubated with SR141716A or SR144528 (Sanofi Recherche, Montepellier, France) as a CB1-or CB2-selective antagonist (13) , respectively, for 1 h before the addition of anandamide. In blastocyst transfer experiments, P 4 -primed ovariectomized pseudopregnant WT recipients received an injection of E 2 (3 ng per mouse) to induce receptive uterus (18) . Dormant blastocysts exposed to the vehicle or anandamide were Abbreviations: CB, cannabinoid receptor; E2, estradiol-17␤; ERK, extracellular regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK͞ERK kinase; P4, progesterone; TS, trophoblast stem. then transferred to these recipients 4 h after an E 2 injection. All recipients were killed 24 h after blastocyst transfers, and the number of implantation sites as demarcated by distinct blue bands was recorded after i.v. injections of Chicago blue B dye solution in saline (19) . Uteri that were devoid of any sign of implantation were flushed to recover unimplanted blastocysts.
Immunofluorescence Detection of CB1, Ca 2؉ Channel ␣ Subunits, and ERK in Blastocysts. To localize CB1 protein and Ca 2ϩ channel ␣ subunits, ␣ 1A (P͞Q-type), ␣ 1B (N-type), and ␣ 1C (L-type), as well as to monitor activation of ERK signaling in blastocysts, immunofluorescences were captured in a Zeiss LSM 510 confocal scanning laser microscope as described (20) . Rabbit polyclonal antibodies specific to CB1 (1 g͞ml, custom made), or ␣ 1A , ␣ 1B , and ␣1C (1 g͞ml, Alomone Labs, Jerusalem), or total and phospho-ERK 1 and 2 (ERK1͞2) (0.5 g͞ml, New England Biolabs) were used.
Ca 2؉ Mobilization and Imaging. Blastocysts were incubated at 37°C for 30 min in Whitten's medium containing 1 M of the cell-permeant acetoxymethyl ester form of fluo-4 and 0.02% pluronic F127 (Molecular Probes) and 2.5 mM probenecid. Preloaded embryos were washed and transferred into Tyrode's solution (150 mM NaCl͞6 mM KCl͞1.5 mM CaCl 2 ͞1 mM MgCl 2 ͞10 mM glucose͞10 mM Hepes, pH 7.4) containing 2.5 mM probenecid, then incubated in the presence or absence of different concentrations of anandamide and͞or selective antagonists to CB1 or CB2 for 30 min. The stimulus for voltage-gated Ca 2ϩ channel activation in blastocysts was a rapid increase in KCl concentration from 6 to 60 mM in the bath solution (21) . To chelate extracellular Ca 2ϩ , 1,2-bis(o-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate (BAPTA, 1 mM) was used in the bath solution instead of CaCl 2 (22) . To identify the relative importance of different Ca 2ϩ channel subtypes in blastocyst function, dormant blastocysts were exposed to 2 M of -Conotoxin GVIA and Calciseptine, selective blockers of N-and L-type Ca 2ϩ channels (22) , respectively, or to 4 M (ϩ͞Ϫ)-Bay K 8644, a selective activator of the L-type Ca 2ϩ channel (23) , in the presence or absence of KCl stimulation. Images were acquired for 5 min after the addition of KCl on a Zeiss LSM 510 confocal scanning laser microscope.
Culture of Trophoblast Stem Cells and Treatment with Cannabinoid
Agonist. A trophoblast stem (TS) cell line derived from mouse blastocysts was used (24) . Immunolocalization of cannabinoid receptors in this cell line was performed as described above and in ref. 20 . TS cell culture and an embryonic fibroblast conditioned media (EMFI-CM) were prepared as described (24) . The TS cell line was maintained in a proliferative state in a medium containing 70% EMFI-CM, 30% TS cell medium, FGF4 (25 ng͞ml), and heparin (1 g͞ml, Sigma) (24) . To study cannabinoid signaling via MAPK activation, TS cells were precultured in the TS medium free of serum, FGF-4, and heparin (differentiation conditions) for 5 h and then challenged with CP55,940, a synthetic cannabinoid agonist (Pfizer Diagnostics). After termination of culture, TS cells were lysed, and lysates (50 g per sample) were analyzed by immunoblotting for total or phosphor-ERK1͞2 (25) . Targeted protein bands were visualized by using chemiluminescent detection reagents (Pierce) and quantitated by using a Molecular Dynamics personal densitometer.
Results and Discussion
CB1 Is Up-Regulated in Dormant Blastocysts. We have previously shown that the levels of anandamide and CB1 are coordinately down-regulated in receptive uteri and activated blastocysts, respectively, before implantation compared with higher levels in delayed uteri and dormant blastocysts that are incompetent for implantation (11) . Our present finding of dramatically upregulated CB1 protein in the trophectoderm of dormant blastocysts and its rapid down-regulation with the termination of delayed implantation with blastocyst activation by estrogen (Fig.  1A) further supports the hypothesis that although lower levels of anandamide and cannabinoid receptors are beneficial for implantation, higher levels are unfavorable to this process.
Anandamide Rapidly Activates ERK Signaling in Blastocysts in a
Dose-Dependent Manner via CB1. We sought to address the mechanism of differential effects of anandamide in blastocyst function and implantation. We first examined whether anandamide at varying levels differentially influences MAPK signaling in blastocysts undergoing experimentally induced dormancy (18, 26, 27) . We observed that anandamide at 7 nM rapidly induced phosphorylation of ERK and its translocation into nuclei of trophectoderm cells of dormant blastocysts within 5 min, showing a peak between 15 and 30 min (Fig. 1B) . In contrast, anandamide at 28 nM failed to induce activation of ERK under similar conditions (Fig. 1C) . In addition, a CB1-selective antagonist SR141716A or a MAPK͞ERK kinase (MEK1͞2) inhibitor U0126 attenuated ERK phosphorylation in the presence of 7 nM anandamide (Fig. 1C) . Pertussis toxin, an inhibitor of G i/o protein-coupled receptors, also attenuated ERK phosphorylation in the presence of anandamide (data not shown). However, total ERK content remained unchanged in dormant blastocysts exposed to 7 nM anandamide or the vehicle (Fig. 1D) . These results provide evidence that ERK activation by anandamide is mediated by G i/o protein-coupled CB1 and suggest that the dose-dependent biphasic function of anandamide in activating ERK signaling via CB1 is physiologically relevant and important for regulating embryonic function for implantation.
To provide genetic evidence that anandamide induced ERK activation in blastocysts is mediated by CB1, we used CB1 Ϫ/Ϫ , CB2 Ϫ/Ϫ and CB1 Ϫ/Ϫ ϫ CB2 Ϫ/Ϫ double mutant blastocysts. Similar to WT blastocysts, anandamide at 7 nM activated ERK phosphorylation in CB2 Ϫ/Ϫ blastocysts (Fig. 1E ) but failed to induce ERK phosphorylation in CB1 Ϫ/Ϫ or CB1 Ϫ/Ϫ ϫ CB2 Ϫ/Ϫ dormant blastocysts (Fig. 1 F and G) . In addition, the selective CB1 antagonist SR141716A inhibited ERK activation by anandamide in CB2 Ϫ/Ϫ dormant blastocysts (Fig. 1E) . ERK activation was also noted in day 4 WT blastocysts by anandamide at 7 nM but not at 28 nM (Fig. 2) . Collectively, these results provide genetic and pharmacological evidence that CB1 is the functional cannabinoid receptor, mediating anandamide singling for MAPK activation in the blastocyst. This is consistent with our previous observation of resistance of CB1 Ϫ/Ϫ or CB1 Ϫ/Ϫ ϫ CB2 Ϫ/Ϫ embryos, but not WT or CB2 Ϫ/Ϫ embryos, to anandamide-mediated effects on preimplantation development in vitro (11) and that a CB2-selective antagonist fails to displace anandamide binding to blastocysts (data not shown).
Cannabinoid Agonist Rapidly Activates ERK Signaling via CB1 in
Differentiating TS Cells. Limited availability of blastocyst tissues prompted us to use a mouse TS cell line, originally generated by Janet Rossant's group (24) , to obtain more quantitative information with respect to ERK signaling in response to cannabinoids. We observed that the differentiating TS cells are decorated with CB1 on their surfaces (Fig. 3A) , similar to the expression pattern on the blastocyst trophectoderm cell surface (Fig. 1 A) . We then asked whether CP55,940, a synthetic cannabinoid agonist, could induce ERK phosphorylation in TS cells; this agonist is effective in inhibiting implantation via CB1 when maintained at an elevated level (10) . Based on results in blastocysts, we initially examined the dose-dependent effects of CP55,940 on ERK activation in TS cells over a period of 15 min. We observed that CP55,940 at 7 nM significantly induced ERK1 phosphorylation with a peak activation at 28 nM, but increasing the concentrations (112 and 448 nM) of CP55,940 did not further enhance ERK1 phosphorylation; rather, a decreasing trend was noted. We then examined the time-dependent activation of ERK phosphorylation at 7 nM of CP55,940 and found that maximal activation occurs at 5 min (Fig. 3 B and C) . A MEK1͞2 inhibitor U0126 or the selective CB1 antagonist SR141716A, but not the CB2 antagonist SR144528, inhibited this activation in the presence of 7 nM CP55,940 ( Fig. 3 B and C) . These results uphold the similar nature of biphasic effect that was observed for anandamide in blastocysts ( Fig. 1 B and C) .
Anandamide at High Concentration Inhibits Depolarization-Induced
Ca 2؉ Influx in Dormant Blastocysts via CB1. Because cannabinoid receptors are negatively coupled to voltage-gated Ca 2ϩ channels (4), we next investigated whether anandamide at low and high levels differentially influences intracellular Ca 2ϩ signaling in blastocysts. We observed that exposure of dormant blastocysts to increased concentration of KCl from 6 to 60 mM rapidly activates Ca 2ϩ influx in the blastocyst trophectoderm with a peak between 30 and 60 sec (Fig. 4) . This KCl-induced Ca 2ϩ mobilization was greatly abolished by chelating extracellular Ca 2ϩ with BAPTA (Fig. 4) , suggesting that voltage-gated Ca 2ϩ channels are present in blastocyst trophectoderm cells. Indeed, the presence of immunoreactive N-and L-type, but not P͞Q-type, Ca 2ϩ channels was detected in the blastocyst trophectoderm cells (Fig. 5A) . We observed that anandamide at 28 nM dramatically inhibited KCl-induced Ca 2ϩ influx, whereas anandamide at 7 nM failed to exhibit such an effect (Fig. 5B) . In addition, this inhibition by 28 nM anandamide was specifically reversed by the CB1-selective antagonist SR141716A, but not by the CB2-selective antagonist SR144528 (Fig. 5B) , suggesting that this effect of anandamide is mediated by blastocyst CB1. Anandamide by itself at a low or high dose did not alter Ca signaling is crucial for blastocyst formation (28) and that N-type Ca 2ϩ channels are functionally coupled to the stimulating effects of heparin-binding EGF-like growth factor (HB-EGF) in blastocyst development and outgrowth (22) .
Anandamide at Low Concentration Confers Blastocyst Competency to
Implantation via CB1. The present observation of ERK activation and inhibition of Ca 2ϩ mobilization, coupled with our previous findings of stimulation and inhibition of trophoblast growth and implantation at low and high cannabinoid levels (11-13), respectively, suggests that cannabinoid-induced stimulatory and inhibitory influences on blastocyst functions and implantation are executed by different signal transduction pathways, such as the ERK and Ca 2ϩ signaling pathways. To obtain further insights into the significance of these observations, we used physiologically relevant models of embryo transfer and delayed implantation. Preimplantation ovarian estrogen secretion on day 4 of pregnancy is essential for implantation. This process is deferred if ovaries are removed before the preimplantation estrogen secretion, resulting in delayed implantation that can be main- tained for many days by continued P 4 treatment with the uterus remaining in a quiescent state and blastocysts in dormancy (18, 26, 27) . Dormant blastocysts, if cultured in vitro, gain metabolic competence (29) . However, we have previously shown that metabolic competency alone fails to confer implantation competency to dormant blastocysts; the gain of implantation competency is also an important factor in the initiation of implantation in the receptive uterus (19) . We show here that dormant blastocysts exposed to 7 nM anandamide, but not 28 nM, become implantation-competent. For example, dormant blastocysts cultured for 24 h in the presence or absence of 7 or 28 nM anandamide were transferred into uterine lumens of P 4 -treated recipients 4 h after an injection of E 2 (3 ng per mouse). Under these conditions, activated blastocysts do implant, whereas dormant blastocysts fail to implant (18, 19) . A large number of blastocysts exposed to 7 nM anandamide showed implantation, whereas those exposed to the vehicle or 28 nM anandamide failed to implant in similarly treated uteri (Table 1) , but no sign of cell death at 28 nM anandamide was noted. A CB1-selective inhibitor SR141716A or a MEK1͞2 inhibitor U0126 blocked the activation of dormant blastocysts for implantation by 7 nM anandamide (data not shown). These results suggest that blastocysts in culture remain implantation-incompetent but gain implantation competency at a lower anandamide concentration in the medium.
To provide genetic confirmation that the effects of anandamide on blastocyst activation are mediated via CB1, CB1 Ϫ/Ϫ dormant blastocysts were cultured for 24 h either in the presence of the vehicle alone or 7 nM anandamide. We observed that most of the CB1 Ϫ/Ϫ dormant blastocysts remained incompetent to implantation in response to 7 nM anandamide (Table 1) . These results provide genetic confirmation that CB1 in the blastocyst interacts with endocannabinoids in a concentration-dependent manner with respect to embryo development and implantation.
The ''window'' of implantation is defined as the time during which the activated stage of the blastocyst is superimposed on the receptive state of the uterus (19) . Our genetic, pharmacological, and physiological analyses show that anandamide at a low concentration activates ERK signaling in dormant blastocysts via their trophectoderm cell surface CB1 and renders them competent for implantation in the receptive uterus. In contrast, failure to achieve ERK activation and implantation competency in blastocysts with the inhibition of Ca 2ϩ mobilization at a higher anandamide level provides evidence that elevated cannabinoid levels are detrimental to blastocyst activation and implantation (Fig. 7 , which is published as supporting information on the PNAS web site). This is consistent with the finding that elevated levels of cannabinoids inhibit implantation in WT mice but not in
double-mutant mice (11) . These results are relevant to humans because spontaneous pregnancy losses occur in women with elevated anandamide levels (30, 31) . Thus, regulated endocannabinoid signaling is at least one of the pathways that determine the fate of embryo implantation. Our present observation of differential regulation of ERK and Ca 2ϩ signaling by anandamide within a very narrow range provides for the first time a potential ''cannabinoid sensor'' mechanism for influencing crucial steps during early pregnancy. We propose that critical levels of uterine endocannabinoids interact with appropriately expressed blastocyst CB1 in synchronizing blastocyst activation with uterine receptivity for implantation, whereas aberrant levels of uterine endocannabinoids and͞or blastocyst CB1 interfere with these processes, resulting in pregnancy termination. In conclusion, this study places the embryo as a target for natural and endocannabinoids and raises the significance of cannabinoid signaling in female fertility.
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